Sucampo Americas Patent-Cliff Exposure & CMS Drug Spending Portfolio
Sucampo Americas (US): 1 reconciled FDA prescription therapies (100.0% 2025 to 2030 cliff risk), $14.9M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 1 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 100.0% |
| Primary Portfolio LOE Date | 2027-01-01 |
| 2024 CMS Total Public Spend | $14.9M |
| 2024 Medicare Part D Spend | $2.9M |
| 2024 Medicaid Spend | $12.0M |
| California HCAI SB 17 Filings | 0 statutory filings in 2023 to 2026 panel |